Evidence map›Paper›PMID 42801586›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Translational Barriers and AI-Driven Challenges of Microfluidics-Enabled Wearables and Implantable Systems in Personalized Medicine.

Ke Huang, Ching Yin Fong, Xin Huang, Bee Luan Khoo

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ke Huang *Department of Biomedical Engineering, College of Biomedicine, City University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0000-0002-5924-7062
Ching Yin Fong *Department of Biomedical Engineering, College of Biomedicine, City University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0009-0004-9910-8843
Xin HuangDepartment of Biomedical Engineering, College of Biomedicine, City University of Hong Kong, Hong Kong, China.
Bee Luan KhooDepartment of Biomedical Engineering, College of Biomedicine, City University of Hong Kong, Hong Kong, China.ORCID https://orcid.org/0000-0003-1100-9994

Funding

City University of Hong Kong 6000963City University of Hong Kong 7006082City University of Hong Kong 7020002City University of Hong Kong 7020073City University of Hong Kong 9609332City University of Hong Kong 9609333City University of Hong Kong 9610787City University of Hong Kong 9678292Innovation and Technology Commission PRP/001/22FXResearch Grants Council (RGC) 8799020Research Grants Council (RGC) 9048206
6 · The paper itself

Abstract

Wearable and implantable microfluidic systems have progressed from laboratory prototypes toward translational clinical deployment, enabling continuous, minimally invasive sampling of dynamic biomarkers across sweat, saliva, tears, and interstitial fluid. However, existing reviews often address materials chemistry or device fabrication in isolation, obscuring the systemic path to clinical translation. This review establishes a cohesive, translation-focused linear trajectory starting from foundational functional biomaterials and advanced fabrication techniques, transitioning into a performance benchmarking of diagnostics-oriented systems and closed-loop theranostic platforms. Through these vectors, we systematically evaluate how microfluidic transport, multiplexed molecular analytics, and autonomous therapeutic integration collectively drive the shift from passive tracking to adaptive intervention. Beyond physical hardware, we decode the integration of artificial intelligence (AI) across three precise pathways: sensor self-calibration, multiplexed molecular decoding, and on-device autonomous decision-making. Finally, we critically examine the socio-technical barriers to clinical translation, with a focus on how biofluid data heterogeneity and population baseline disparities propagate algorithmic bias. We propose that robust hardware interfaces, standardized validation benchmarks, and alignment with emerging regulatory frameworks are prerequisites for achieving equitable, responsible digital health protection.

Indexed as

AI‐driven biomarker analyticsclosed‐loop drug deliverymicrofluidicpersonalized medicinewearable biosensors

Identifiers

PMID42801586
PMCPMC13616331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.